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Abstract
Background: Noninvasive biomarkers are needed to guide metastatic castration-resis-
tant prostate cancer (mCRPC) treatment.
Objective: To clinically qualify baseline and on-treatment cell-free DNA (cfDNA) con-
centrations as biomarkers of patient outcome following taxane chemotherapy.
Design, setting, and participants: Blood for cfDNA analyses was prospectively collected
from 571 mCRPC patients participating in two phase III clinical trials, FIRSTANA
(NCT01308567) and PROSELICA (NCT01308580). Patients received docetaxel (75 mg/
m2) or cabazitaxel (20 or 25 mg/m2) as ﬁrst-line chemotherapy (FIRSTANA), and
cabazitaxel (20 or 25 mg/m2) as second-line chemotherapy (PROSELICA).
Outcome measurements and statistical analysis: Associations between cfDNA concen-
tration and prostate-speciﬁc antigen (PSA) response were tested using logistic regres-
sion models. Survival was estimated using Kaplan-Meier methods for cfDNA
concentration grouped by quartile. Cox proportional hazard models, within each study,
tested for associations with radiological progression-free survival (rPFS) and overall
survival (OS), with multivariable analyses adjusting for baseline prognostic variables.
Two-stage individual patient meta-analysis combined results for cfDNA concentrations
for both studies.
Results and limitations: In 2502 samples, baseline log10 cfDNA concentration correlated
with known prognostic factors, shorter rPFS (hazard ratio [HR] = 1.54; 95% conﬁdence
interval [CI]: 1.15–2.08; p = 0.004), and shorter OS on taxane therapy (HR = 1.53; 95% CI:
1.18–1.97; p = 0.001). In multivariable analyses, baseline cfDNA concentration was an
independent prognostic variable for rPFS and OS in both ﬁrst- and second-line chemo-
therapy settings. Patients with a PSA response experienced a decline in log10 cfDNA
concentrations during the ﬁrst four cycles of treatment (per cycle 0.03; 95% CI: 0.044
to 0.009; p = 0.003). Study limitations included the fact that blood sample collectionor a
on was not mandated f
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Conclusions: We report that changes in cfDNA concentrations correlate with both rPFS
and OS in patients receiving ﬁrst- and second-line taxane therapy, and may serve as
independent prognostic biomarkers of response to taxanes.
Patient summary: In the past decade, several new therapies have been introduced for
men diagnosed with metastatic prostate cancer. Although metastatic prostate cancer
remains incurable, these novel agents have extended patient survival and improved their
quality of life in comparison with the last decade. To further optimise treatment
allocation and individualise patient care, better tests (biomarkers) are needed to guide
the delivery of improved and more precise care. In this report, we assessed cell-free DNA
in over 2500 blood samples from men with prostate cancer who were recruited to two
separate international studies and received taxane chemotherapy. We quantiﬁed the
concentration of cell-free DNA fragments in blood plasma, which partly originates from
tumour. We identiﬁed that higher concentrations of circulating cell-free DNA fragments,
prior to starting taxane chemotherapy, can be used to identify patients with aggressive
prostate cancer. A decline in cell-free DNA concentration during the ﬁrst 3–9 wk after
initiation of taxane therapy was seen in patients deriving beneﬁt from taxane chemo-
therapy. These results identiﬁed circulating cell-free DNA as a new biomarker of
aggressive disease in metastatic prostate cancer and imply that the study of cell-free
DNA has clinical utility, supporting further efforts to develop blood-based tests on this
circulating tumour-derived DNA.
© 2018 European Association of Urology. Published by Elsevier B.V. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Prostate cancer (PCa) remains a major global healthcare
challenge and lethal PCa remains a major cause of male
cancer deaths [1]. Although most men with metastatic
hormone-sensitive PCa respond well to androgen depriva-
tion therapy (ADT) alone, their disease invariably recurs as
metastatic castration-resistant prostate cancer (mCRPC).
Docetaxel was introduced as a life-prolonging treatment for
mCRPC in 2004, with taxanes gaining importance in the
management of mCRPC [2,3]. The TROPIC trial led to
cabazitaxel being registered as a second-line taxane in 2010
[4]. Furthermore, the CHAARTED and STAMPEDE trials
brought docetaxel to the hormone-sensitive setting in 2015,
showing unprecedented survival benefit in combination
with ADT for patients with metastatic disease [5,6].
Other approved therapies for mCRPC include abirater-
one, enzalutamide, radium-223, and sipuleucel-T; however,
no optimal sequence of treatment or patient selection
strategies have yet been established [7]. Currently, patients
are assigned specific treatment types pragmatically, often
with fitter patients prescribed chemotherapy, and less toxic
drugs assigned earlier [8]. Identifying patients who are
likely to benefit from specific treatment options remains a
critically important unmet clinical need, and biomarkers
predictive of early response to taxane therapy would help
minimise overtreatment.
Potential use of cell-free DNA (cfDNA) as a prognostic
and predictive biomarker of PCa, facilitating diagnosis and
response to treatment, has been suggested [9–11]. In
healthy volunteers, cfDNA levels are <5 ng/ml and reported
to largely arise from haematopoietic cells [12]. Conversely,
elevated cfDNA concentrations are present in the plasma of
patients with PCa, where it comprises both circulating
tumour DNA and normal DNA, with tumour content
averaging 30%. Circulating tumour DNA has been reported
to represent multiple tumour sites and is released through
necrosis, apoptosis, and even active secretion [13,14].Please cite this article in press as: Mehra N, et al. Plasma Cell-fre
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genetic and epigenetic, and quantitative analyses [13,15–
17]. In a study of patients with various advanced cancers,
the median cfDNA concentration was 17 ng/ml, with the
highest concentrations (53 ng/ml) seen in patients with
mCRPC [18].
This substudy assessed the clinical utility of plasma
cfDNA in patients with mCRPC who also received taxanes
(docetaxel and cabazitaxel) in two phase III clinical trials
(FIRSTANA [NCT01308567] and PROSELICA [NCT01308580]).
We performed preplanned analyses of baseline and serial
blood samples taken from 571 consenting patients, and
investigated the prognostic value of baseline cfDNA concen-
tration and whether changes in cfDNA concentration during
the first 9 wk of taxane chemotherapy are associated with
response.
2. Patients and methods
2.1. Patients
This study included patients participating in two prospective, random-
ised, open-label, international phase III trials: FIRSTANA (NCT01308567),
evaluating superiority of cabazitaxel 20 mg/m2 (n = 389) or cabazitaxel
25 mg/m2 (n = 388) over docetaxel 75 mg/m2 (n = 391), each with 10 mg/
d prednisone, as ﬁrst-line chemotherapy for patients with mCRPC [19];
and PROSELICA (NCT01308580), a noninferiority study evaluating
cabazitaxel 20 mg/m2 (n = 598) or 25 mg/m2 (n = 602) with 10 mg/d
prednisone, as second-line therapy for patients with mCRPC who
progressed on docetaxel [20]. These study designs are shown in
Supplementary Figure 1. The primary end point of both studies was
overall survival (OS). Secondary end points included radiological
progression-free survival (rPFS), tumour response in patients with
measurable disease, and prostate-speciﬁc antigen (PSA) response (50%
response at week 12; 50% response at any time). As part of preplanned
biomarker analysis, baseline and serial blood samples were collected
from consenting patients for quantitative and qualitative evaluation of
plasma cfDNA. Analyses of cfDNA were included in both PROSELICA and
FIRSTANA study protocols; however, details of statistical analyses were
not prespeciﬁed and are therefore to be considered exploratory.e DNA Concentration and Outcomes from Taxane Therapy in
 Trials (FIRSTANA and PROSELICA). Eur Urol (2018), https://doi.
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Blood was collected in heparinised plasma tubes (BD Vacutainer; BD
Biosciences, San Jose, CA, USA) at screening, prior to commencing cycle
1 (C1; baseline), C2, and C4, and at the end of treatment. Baseline
samples (screening and C1) were taken between 1 and 7 d apart. Cell-
free DNA was isolated from 1 ml of plasma using QIAamp Circulating
Nucleic Acid kit (Qiagen, Hilden, Germany), as per the manufacturer's
protocol. Of the 50 ml eluate, 10 ml was used for quantiﬁcation in
duplicates using the Quant-IT Picogreen HS DNA kit (ThermoFisher,
Waltham, Massachussets, USA), utilising a BioTek microplate spectro-
photometer at 480ex/520em.
2.3. Statistical analyses
Baseline characteristics of patients selected for the biomarker substudy
were compared with those of patients not selected using x2 test and t test
as indicated. Baseline characteristics were compared between trials
using x2 test and t test as indicated. To evaluate the biological variability
of cfDNA, the coefﬁcient of variation was calculated from both screening
and C1 baseline plasma log10 cfDNA concentration. For all subsequent
analyses, the average of the two baseline samples was used, unless only a
single baseline was available. Pearson's correlation (r) was tested for
associations between baseline log10 cfDNA concentration and other
continuous baseline prognostic variables. Median rPFS and OS were
estimated using the Kaplan-Meier method, and multivariable Cox
proportional hazard models tested for associations with rPFS and OS.
The proportional hazards assumption was tested using Schoenfeld
residuals, but not found to be violated for log10-transformed cfDNA
concentration. Multivariable analyses were adjusted for the trial,
randomised treatment, baseline Eastern Cooperative Oncology Group
(ECOG) performance status, Gleason score, visceral disease, bone-only
disease, pain at baseline, albumin, alkaline phosphatase (ALP), haemo-
globin, lactate dehydrogenase (LDH), neutrophil-to-lymphocyte ratio
(NLR), and PSA. Approximately 22% of patients were missing one or more
of these variables, and these were considered to be missing at random. To
ensure no loss in the efﬁciency of multivariable analyses, multiple
imputation by chained equations with the above coefﬁcients was used to
generate 20 imputations and per imputation estimates were combined
using Rubin's rules. The value of adding baseline cfDNA to models of rPFS
and OS was assessed by calculating Uno's inverse-probability weighted
C-index and receiver operating characteristic (ROC) area under the curve
(AUC) values [21]. Bootstrapping was used to calculate the 95%
conﬁdence interval (CI) and the difference (delta) between C-indices
of each of the models. Time-dependent incident dynamic ROC curves
(with 19-mo OS and 10-mo rPFS end point, which represents the median
survival of the dataset) and time-dependent AUC curves were calculated
according to the method proposed by Blanche et al [22]. The change at C2
and C4 from baseline was calculated (DcfDNA). Associations between
log10 cfDNA concentration, DcfDNA, and DcfDNA cut-off (>20% and
>30% change) and PSA response were tested using per study logistic
regression models. Cox models, utilising a landmark approach, assessed
the association between these cfDNA values and OS and rPFS. Two-stage
individual patient meta-analyses combined results for per-study logistic
regression and Cox model analyses of average baseline log10 cfDNA
concentration; results are displayed using forest plots. Linear mixed-
effect models of log10 cfDNA concentrations during the ﬁrst four cycles,
with random patient intercept effects nested within random study
intercept effects, assessed the association of patient characteristics.
Characteristics included PSA response at any time, a PSA ﬂare during the
ﬁrst 12 wk (deﬁned as any increase followed by a 50% decline in PSA from
baseline), and white blood cell (WBC) count at week 2. All p values <0.05
were considered signiﬁcant. Stata v13, R v3.4.1, SPSS Statistics for
Macintosh v22.0 (IBM Corp, Armonk, NY, USA), and GraphPad PrismPlease cite this article in press as: Mehra N, et al. Plasma Cell-fre
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used for statistical analyses and ﬁgures.
3. Results
3.1. Patients and samples
Overall, 571 patients with mCRPC (315 of 1168 patients
enrolled in FIRSTANA and 256 of 1200 patients enrolled in
PROSELICA) were included between April 2011 and Decem-
ber 2013 in this substudy evaluating the association
between cfDNA concentration and outcomes from taxane
chemotherapy. A total of 1400 patient samples from
FIRSTANA and 1102 from PROSELICA were available. Patient
baseline characteristics are presented in Table 1. Baseline
characteristics of patients included in the biomarker
substudy, compared with those who were not included,
are presented in Supplementary Table 1. An imbalance in
baseline characteristics was seen in FIRSTANA substudy
patients for baseline pain, Gleason score, haemoglobin,
albumin, and ALP. FIRSTANA included a docetaxel-naïve
population, whereas PROSELICA included a postdocetaxel
population with more advanced disease, with patients
having higher ECOG performance status, LDH, ALP, and PSA
levels and a lower haemoglobin concentration. In FIRSTANA,
203 patients died and 149 patients radiologically pro-
gressed, and in PROSELICA, 220 patients died and
142 patients radiologically progressed. The median fol-
low-up periods for patients who did not die were 33 and
27mo for FIRSTANA and PROSELICA, respectively. The
median follow-up periods for patients who did not
experience radiological progression were 8 and 5 mo for
FIRSTANA and PROSELICA, respectively. PSA responses,
defined as confirmed 50% PSA falls by the Prostate Cancer
Working Group 2 definition, were 68% and 43% in FIRSTANA
and PROSELICA, respectively (p < 0.001).
3.2. Baseline cfDNA concentrations
We first evaluated the biological variability in log10 cfDNA
concentration between the two baseline samples, taken
between 1 and 7 d apart, and collected in 507 (89%) patients.
Both baseline sample concentrations correlated well (-
r = 0.84, p < 0.001), with a mean coefficient of variation
between the biological replicate samples of 12% (95% CI: 11–
13%; Fig. 1). There was a robust correlation between log10
cfDNA concentration and established prognostic variables
[23,24], including log10 LDH (r = 0.46, p < 0.001, n = 566),
haemoglobin (r = 0.45, p < 0.001, n = 570), log10 ALP
(r = 0.40, p < 0.001, n = 569), and log10 PSA (r = 0.34,
p < 0.001, n = 568), with a weak association with white
blood cells (r = 0.14, p = 0.001, n = 570) and albumin
(r = 0.12, p = 0.004, n = 560). All prognostic variables and
their relationship with baseline log10 cfDNA concentration
in FIRSTANA and PROSELICA are presented in Supplemen-
tary Table 2, with ECOG performance status, presence of
pain at baseline, ALP, haemoglobin concentration, LDH, PSA
doubling time, and NLR associating significantly with cfDNA
in both trials.e DNA Concentration and Outcomes from Taxane Therapy in
 Trials (FIRSTANA and PROSELICA). Eur Urol (2018), https://doi.
Table 1 – Baseline characteristics
Characteristic FIRSTANA
n = 315
PROSELICA
n = 256
p value a
N (%) N (%)
ECOG PS b
0–1 305 (97) 235 (92) 0.008
2 10 (3) 21 (8)
RECIST measurable b
No 141 (45) 121 (47) 0.8
Yes 174 (55) 135 (53)
Visceral disease
No 245 (78) 183 (71) 0.08
Yes 70 (22) 73 (29)
Pain at baseline c
No 79 (28) 60 (26) 0.9
Yes 208 (72) 171 (74)
Gleason score at diagnosis d
<8 117 (39) 117 (49) 0.02
8 182 (61) 122 (51)
Trial arm
Cabazitaxel 20 mg/m2 111 (35) 120 (47) <0.001
Cabazitaxel 25 mg/m2 89 (28) 136 (530
Docetaxel 75 mg/m2 115 (37) 0 (0)
Median (IQR) Median (IQR) p value e
Age (yr) 69 (63–74) 68 (64–73) 0.9
LDH (U/l) 234 (188–350) 331 (221–547) <0.001
ALP (U/l) 113 (77–243) 178 (96–387) <0.001
Haemoglobin (g/dl) 130.0 (119.2–137.0) 119.0 (106.0–127.5) <0.001
Albumin (g/dl) 40.0 (37.5–43.0) 40.7 (37.0–43.1) 0.7
PSA (ng/ml) 80.0 (30.0–189.0) 207.6 (59.7–598.9) <0.001
PSA doubling time (mo) 2.1 (1.3–3.4) 1.9 (1.3–3.1) 0.3
Log10 cfDNA concentration
(ng/ml)
1.21 (0.97–1.54) 1.45 (1.18–1.86) <0.001
NLR 3.0 (2.1–4.3) 3.7 (2.4–5.7) <0.001
Outcome N (%) N (%) p value a
>50% PSA response at 12 wk
No 141 (46) 165 (69) <0.001
Yes 163 (54) 73 (31)
>50% PSA response at any time
No 96 (32) 136 (57) <0.001
Yes 208 (68) 102 (43)
Median (IQR) Median (IQR) HR (95% CI)
p value f
rPFS (mo) 11.6 (7.9–18.2) 8.1 (4.2–12.7) 0.53
(0.42–0.68) <0.001
OS (mo) 25.6 (13.2–39.7) 14.4 (8.0–21.4) 0.42
(0.35–0.52) <0.001
ALP = alkaline phosphatase; cfDNA = cell-free DNA; CI = conﬁdence interval; ECOG PS = Eastern Cooperative Oncology Group performance status; HR = hazard
ratio; IQR = interquartile range; LDH = lactate dehydrogenase; NLR = neutrophil-lymphocyte ratio; OS = overall survival; PSA = prostate-speciﬁc antigen;
RECIST = Response Evaluation Criteria in Solid Tumours; rPFS = radiological progression-free survival; U = unit.
a 2 test.
b Stratification parameters.
c Fifty-three assessments missing (28 in FIRSTANA and 25 in PROSELICA).
d Thirty-three assessments missing (16 in FIRSTANA and 17 in PROSELICA).
e Wilcoxon rank-sum test.
f Proportional hazards Cox model.
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response to taxanes
Univariable logistic regression analyses indicated that
baseline log10 cfDNA concentration was not associated with
a confirmed PSA response in either FIRSTANA (odds ratio
[OR] = 0.91; p = 0.7) or PROSELICA (OR = 0.76; p = 0.3), or in
a two-stage meta-analysis combining results from bothPlease cite this article in press as: Mehra N, et al. Plasma Cell-fre
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larly, there was no evidence that baseline log10 cfDNA
concentration was associated with radiological response
(Supplementary Fig. 2).
We next evaluated the effect of taxane chemotherapy on
longitudinal log10 cfDNA concentration during treatment.
Mean plasma cfDNA concentration decreased during the
first four cycles following chemotherapy initiation, consis-e DNA Concentration and Outcomes from Taxane Therapy in
 Trials (FIRSTANA and PROSELICA). Eur Urol (2018), https://doi.
Fig. 1 – Correlation and coefficient of variation between both baseline samples taken between 1 and 7 d apart. (A) Relationship between log10-
transformed cfDNA concentration (ng/ml) at screening and at C1 in 507 paired samples derived from n = 571 patients. Correlation coefficient = 0.84
(Pearson's rho) with p < 0.001. (B) CV of baseline samples depicted in a frequency chart with mean and median CV of 0.12 and 0.08 with 95% CI of
0.11 and 0.13, respectively. Mean CV is shown in solid line. C = cycle; cfDNA = cell-free DNA; CI = confidence interval; CV = coefficient of variation.
Table 2 – Change in plasma cfDNA concentration (log10 ng/ml) from baseline in FIRSTANA and PROSELICA
FIRSTANA PROSELICA
Change in Log10 plasma cfDNA concentration (ng/ml) Mean change 95% CI n Mean change 95% CI n
Cycle 2 (week 4) 0.04 0.08 to 0.007 280 0.07 0.12 to 0.02 231
Cycle 4 (week 10) 0.04 0.09 to 0.00 244 0.07 0.13 to 0.02 189
End of treatment 0.07 0.01–0.13 255 0.10 0.02–0.17 193
cfDNA = cell-free DNA; CI = conﬁdence interval.
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baseline to the end of treatment in observance with disease
progression. This trend was most obvious in the PROSELICA
samples, already apparent at C2 following treatment
initiation and reaching significance at C4 (Table 2). This is
illustrated in Figure 2.
A multivariable mixed-effect model, displayed in Sup-
plementary Table 3, analysed predictors of cfDNA concen-
trations during the first four cycles of treatment. There was
no evidence of a difference in baseline cfDNA concentra-
tions by PSA response (a 50% decline at any time) or of an
overall per cycle change in cfDNA concentrations. Patients
who had a PSA response (a 50% decline at any time) had
lower per-cycle log10 cfDNA concentrations (0.026;
0.044 to 0.009; p = 0.003) after adjusting for other
baseline characteristics. There was no evidence that a PSA
flare, experienced by 28/571 (4.9%) patients, influenced
log10 cfDNA concentration.Fig. 2 – Mean log10 cfDNA concentrations and 95% confidence intervals
per cycle by PSA response (decrease of 50% at any time). cfDNA = cell-
free DNA; PSA = prostate-specific antigen.
Please cite this article in press as: Mehra N, et al. Plasma Cell-fre
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concentration, absolute change in log10 cfDNA concentra-
tion (at C2 compared with baseline or DcfDNA C2), and a
>20% decline in log10 cfDNA concentration (at C2 compared
with baseline) were associated with PSA response in
PROSELICA. Analyses of samples at C4 (week 10) demon-
strated that cfDNA parameters were significantly associated
with PSA response in both studies; the absolute change in
log10 cfDNA concentration (at C4 compared with baseline or
DcfDNA C4) had an OR of 0.4 (95% CI: 0.2–0.7; p = 0.002) and
0.3 (95% CI: 0.2–0.6; p < 0.001) in FIRSTANA and PROSELICA,
respectively, as well as in two-stage meta-analysis (OR 0.3;
95% CI: 0.2-0.5; p < 0.001). All other exploratory parameters
and time points are given in Supplementary Table 4.
3.4. Radiological progression-free survival
Median rPFS was 17, 11, 10, and 11 mo in FIRSTANA, and 12,
10, 8, and 6 mo in PROSELICA for patients grouped by log10
cfDNA concentration from the lowest to the highest quartile
(Fig. 3A). Multivariable survival analyses of baseline
prognostic factors and rPFS for both studies combined are
shown in Table 3; log10 cfDNA had an HR of 1.54 (95% CI:
1.15–2.08; p = 0.004). Uno's C-index for this model with
time truncated at 24 mo was 0.70 (95% CI: 0.67–0.73), and
this model did not provide significantly improved model fit
compared with the model without log10 cfDNA (C-index:
0.69; 95% CI: 0.66–0.73; delta = 0.006; 0.003 to 0.02;
p = 0.2). The area under the time-dependent ROC curve for
the model with cfDNA at 10 mo was 0.78 (95% CI: 0.73–0.84)
and was not significantly different from that for the model
without cfDNA (p = 0.5; Supplementary Fig. 3). In both
studies, post-treatment log10 cfDNA concentration at C2 and
C4 was associated similarly with rPFS. Combined study
estimates for log10 cfDNA concentration at C2 and C4 were
HR = 1.89 (95% CI: 1.36–2.63; p < 0.001) and HR = 1.88 (95%e DNA Concentration and Outcomes from Taxane Therapy in
 Trials (FIRSTANA and PROSELICA). Eur Urol (2018), https://doi.
Fig. 3 – Correlation of baseline cfDNA concentration quartiles with rPFS and OS. (A) Kaplan-Meier curve of rPFS by baseline log10 cfDNA concentration
quartiles. (B) Forest plot for rPFS (multivariable analysis model) for baseline log10 cfDNA concentration for each study and combined estimate. (C)
Kaplan-Meier curve of OS by baseline cfDNA concentration quartiles. (D) Forest plot for OS (multivariable analysis model) for baseline log10 cfDNA
concentration for each study and combined estimate. The multivariable Cox model included baseline log10 cfDNA concentration, ECOG PS at baseline
(0 vs 1–2), visceral metastases, bone-only disease, Gleason score, baseline pain, baseline albumin, baseline ALP, baseline haemoglobin, baseline LDH,
baseline NLR and baseline PSA. The I2 test displays and tests the level of heterogeneity between the studies, which is nonsignificant for cfDNA.
ALP = alkaline phosphatase; cfDNA = cell-free DNA; CI = confidence interval; ECOG PS = Eastern Cooperative Oncology Group performance status; HR,
= hazard ratio; LDH = lactate dehydrogenase; NLR = Neutrophil-lymphocyte ratio; OS = overall survival; PSA = prostate-specific antigen;
rPFS = radiological progression-free survival.
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Table 3 – Multivariable analyses of PFS and OS
Baseline characteristics rPFS OS
aHR 95% CI p value aHR 95% CI p value
Log10 cfDNA 1.54 1.15–2.08 0.004 1.53 1.18–1.97 0.001
ECOG PS
0–1 1.00 – – 1.00 – –
2 1.16 0.68–1.96 0.7 1.15 0.76–1.74 0.5
Visceral disease
No 1.00 – – 1.00 – –
Yes 1.77 1.33–2.36 <0.001 1.46 1.15–1.86 0.002
Bone-only disease
No 1.00 – – 1.00 – –
Yes 0.54 0.39–0.75 <0.001 0.79 0.62–1.01 0.06
Gleason score
<8 1.00 – – 1.00 – –
8 1.43 1.11–1.85 0.006 1.17 0.95–1.44 0.13
Baseline pain
No 1.00 – – 1.00 – –
Yes 1.20 0.88–1.63 0.3 1.29 1.00–1.67 0.06
Study
FIRSTANA 1.00 – – 1.00 – –
PROSELICA 1.49 1.11–2.00 0.008 1.65 1.29–2.13 <0.001
Trial arm
Cabazitaxel 20 mg/m2 1.00 – 0.8 1.00 – 0.6
Cabazitaxel 25 mg/m2 1.00 0.77–1.30 – 0.91 0.73–1.13 –
Docetaxel 75 mg/m2 1.14 0.79–1.64 – 1.04 0.77–1.41 –
LDH (Log10 U/l) 2.40 1.32–4.37 0.004 2.41 1.43–4.05 0.001
ALP (Log10 U/l) 1.12 0.78–1.61 0.5 1.53 1.14–2.04 0.004
Haemoglobin (g/dl) 0.85 0.77–0.94 <0.001 0.86 0.79–0.94 <0.001
Albumin (g/dl) 1.00 0.85–1.17 1 1.04 0.87–1.25 0.7
PSA (log10 ng/ml) 0.86 0.72–1.03 0.10 1.03 0.87–1.21 0.7
NLR (log10) 1.42 0.88–2.28 0.2 1.78 1.18–2.70 0.006
ALP = alkaline phosphatase; cfDNA = cell-free DNA; CI = conﬁdence interval; ECOG PS = Eastern Cooperative Oncology Group performance status;
aHR = adjusted hazard ratio; LDH = lactate dehydrogenase; NLR = neutrophil-lymphocyte ratio; OS = overall survival; PFS = progression-free survival;
PFS = progression-free survival; PSA = prostate-speciﬁc antigen; rPFS = radiological progression-free survival; U = unit.
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evidence that the absolute change in log10 cfDNA concen-
tration was associated with rPFS at C2 (HR = 1.12; 0.78–1.59;
p = 0.5) or C4 (HR = 1.37; 95% CI: 0.92–2.02; p = 0.12) in the
combined study estimates.
3.5. Overall survival
Median OS for patients in FIRSTANA and PROSELICA was 39,
30, 22, and 15 mo, and 18, 18, 12, and 9 m, respectively, for
patients grouped by cfDNA concentration from the lowest to
the highest quartile (Fig. 3C). Multivariable survival
analyses of baseline prognostic factors and rPFS for both
studies combined are shown in Table 3; log10 cfDNA had an
HR of 1.53 (95% CI: 1.18–1.97; p = 0.001). Uno's C-index for
this model with time truncated at 36 mo was 0.73 (95% CI:
0.70–0.75), although this model did not provide signifi-
cantly improved model fit compared with the model
without log10 cfDNA (C-index: 0.72; 95% CI: 0.70–0.75;
delta = 0.004; 0.0009 to 0.008; p = 0.12). The area under
the time-dependent ROC curve for the model with cfDNA at
19 mo was 0.82 (95% CI: 0.78–0.86) and was significantly
higher than that for the model without cfDNA (p = 0.05;
Supplementary Fig. 3). Comparing combined study–esti-
mated OS of patients with post-treatment samples, results
show that HR = 1.77 (95% CI: 1.37–2.29; p < 0.001) and
HR = 1.75 (95% CI: 1.30–2.35; p < 0.001) at C2 and C4,Please cite this article in press as: Mehra N, et al. Plasma Cell-fre
Metastatic Castration-resistant Prostate Cancer from Two Phase III
org/10.1016/j.eururo.2018.02.013respectively. There was no evidence of an association
between the absolute change in log10 cfDNA concentration
in the post-treatment samples and OS (C2 HR = 1.26; 95% CI:
0.94–1.68; p = 0.12; C4 HR = 1.29; 95% CI: 0.92–1.79;
p = 0.14) in the combined study estimates.
4. Discussion
Quantitative assessment of plasma cfDNA levels can
facilitate the diagnosis of PCa and predict biochemical
recurrence following prostatectomy [9–11,25,26]. Previous
small, mainly retrospective studies also indicated a
relationship between baseline cfDNA concentration and
OS [18,27]. One of these studies evaluated 59 patients with
mCRPC following first-line docetaxel or second-line caba-
zitaxel chemotherapy, suggesting a correlation between
baseline median cfDNA concentration levels and extent of
PSA decline [27]. A study of eight patients with mCRPC
following docetaxel chemotherapy suggested a possible
correlation between baseline cfDNA concentration and
radiological response [28].
Our study, of 751 patients treated with taxane chemo-
therapy enrolled in two phase III trials, revealed that cfDNA
concentration at baseline correlated with both rPFS and OS.
Changes in cfDNA concentration during taxane treatment
were associated with biochemical response, but baseline
cfDNA levels showed no relationship with biochemical ore DNA Concentration and Outcomes from Taxane Therapy in
 Trials (FIRSTANA and PROSELICA). Eur Urol (2018), https://doi.
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differences in prognostic variables, and between first- and
second-line chemotherapy. This correction was not per-
formed in the study by Kienel and colleagues [27], likely
biasing the conclusions, since higher responses are ob-
served in first-line patients who are more likely to have
lower cfDNA concentrations. A study by Kwee and
colleagues [28] reported an increase in cfDNA concentration
following one and three cycles of docetaxel; in contrast, our
analyses of cfDNA concentration showed distinctive kinet-
ics of cfDNA following taxane chemotherapy between
responders and nonresponders. Both FIRSTANA and PRO-
SELICA studies observed a significant decline in cfDNA at
week 10 in responding patients; in the second-line setting, a
decline as early as week 4 after therapy was found to be
associated with response. In summary, our data extend our
knowledge on the prognostic value of cfDNA in patients
with PCa. Limited additional value was seen following
incorporation of cfDNA levels to prognostic models, and
cfDNA level changes could not predict response to agent or
dose level. In addition, changes in cfDNA following
treatment did not meet surrogacy criteria of OS, defined
by Prentice [29], as the effect of treatment on survival was
not captured by this. Our study did not include internal
validation, as we felt this was inappropriate due to
differences in disease stages between study populations.
Therefore, external validation is still warranted to confirm
the clinical utility of quantitative cfDNA assessment as a
prognostic biomarker.
There are limitations to cfDNA analyses in patient
plasma. Plasma collection for cfDNA analyses in these
two large trials was optional, resulting in only a proportion
of patients having this collected. Baseline characteristics
were not matched for recruited biomarker substudy
patients in FIRSTANA; therefore, extrapolation of our results
to the full dataset may only be made following correction
for imbalances. Integrity of cfDNA may be compromised in
the transportation, storage, and handling of samples; it has
been shown that plasma cfDNA degrades by 30% for each
year of storage [30,31]. Other factors include high inter-
patient variability in cfDNA concentration. Although levels
are generally found to be much higher in cancer patients
than healthy volunteers, there is a significant degree of
overlap, with a higher cfDNA concentration linked to
inflammation as well as neoplasia [32]. Our results indeed
imply that cfDNA constitutes both circulating tumour DNA
and normal DNA, with haemoglobin, LDH, WBC, and PSA
levels best explaining cfDNA levels. Changes in cfDNA levels
were best explained by changes in tumour burden
measures, LDH, and PSA decline. Of note, samples obtained
from FIRSTANA and PROSELICA participants were stored for
less than a year before cfDNA extraction, and the high
concordance of biological replicates observed in this study
suggests that compromised integrity was highly unlikely.
Another limitation to the interpretation of our data and
the clinical utility of cfDNA as a prognostic biomarker is
theoretically due to different proportions of tumour DNA
constituting the total cfDNA concentration; this can vary
significantly across tumour types, with circulating tumourPlease cite this article in press as: Mehra N, et al. Plasma Cell-fre
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org/10.1016/j.eururo.2018.02.013DNA concentration between 0.01% and 95% [14,15,33]. Esti-
mation of tumour content by bioinformatic algorithms
incorporating information from single nucleotide polymor-
phisms and clonal mutations are evaluated in these
samples, potentially increasing the utility of cfDNA as a
biomarker.
5. Conclusions
Our study identifies baseline cfDNA concentration as an
independent prognostic biomarker in patients with mCRPC,
with higher baseline concentrations associated with shorter
rPFS and OS following taxane therapy. A decline in total
cfDNA concentration during the first 9 wk of treatment was
associated with response to taxane therapy. This study is
part of ongoing efforts to clinically qualify the utility of
cfDNA in the management of advanced PCa patients.
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